Name:
`
`Position:
`
`
`
`
`
`CURRICULUM VITAE
`
`
`Soumyajit Majumdar
`
`Associate Dean for Research and Graduate Programs, School of Pharmacy
`Professor, Pharmaceutics and Drug Delivery
`Research Professor, Research Institute of Pharmaceutical Sciences
`Associate Director, Pii Center for Pharmaceutical Technology
`Co-Director Hands-on Course in Tablet Technology
`
`Office Address
`
`
`
`
`111 Faser Hall
`Department of Pharmaceutics and Drug Delivery
`The University of Mississippi
`University, MS, 38677.
`
`Email
`
`majumso@olemiss.edu
`
`Education:
`
`
`
`
`
`Bachelor of Pharmacy, 1989
`Jadavpur University, Calcutta, India
`Master of Pharmacy, 1991
`Jadavpur University, Calcutta, India
`Doctor of Philosophy, 2005
`Pharmaceutical Sciences and Pharmacology
`University of Missouri-Kansas City, MO, USA.
`
`
`
`PROFESSIONAL EXPERIENCE
`7/16 – to date Organization: The University of Mississippi
` Title:
`
` Professor, Department of Pharmaceutics, School of
`Pharmacy and Research Professor, RIPS
`
`3/15 - to date Organization: The University of Mississippi
`Title
`: Associate Dean for Research and Graduate Programs
`
`7/12 – to date Organization: The University of Mississippi
`Title
`: Associate Director, Pii Center for Pharmaceutical Technology
`
`7/11 – 6/16 Organization: The University of Mississippi
`Title
`: Associate Professor, Department of Pharmaceutics, School of
`Pharmacy and Research Associate Professor, RIPS
`
`7/05 – 6/11 Organization: The University of Mississippi
`Title
`: Assistant Professor, Department of Pharmaceutics, School of
`Pharmacy. and Research Assistant Professor, RIPS
`
`
`
`
`
`
`6/99 to 7/00: Company: Orchid Healthcare, Chennai, India
`
`
`Title:
`
`Deputy Manager Formulation Development
`
`5/97 to 6/99 Company:
`
`
`Title:
`
`
`Novartis Enterprises Pvt. Ltd. Mumbai, India
`Senior Executive (Group Leader) Research and
`Development
`
`ALCON 2024
`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`

`

`Executive, Research and Development (Sandoz India
`
`Title:
`93 to 4/97
`
` Ltd.which became Novartis)
`
`4/92 to 93
`Title:
`
`Production Officer (Sandoz India Ltd.)
`
`6/91 to 4/92 Title:
` Management Trainee, Manufacturing (Sandoz India Ltd.)
`
`
`
`ACHIEVEMENTS:
`
`AWARDS / HONORS
`
`Lipid-based Drug Delivery Outstanding Researcher Award 2014, Lipid based drug
`delivery focus group, American Association of Pharmaceutical Scientists.
`
`Pharmaceutical Sciences Teacher of the Year Award, The University of Mississippi.
`(2013-2014)
`
`Bachelor of Science in Pharmaceutical Sciences Teacher of the Year, The University of
`Mississippi, 2011-2012
`
`New Investigator Research Award, The University of Mississippi, 2010-2011
`
`Associates Grant Award. The University of Mississippi, 2007 – 2008
`
`
`
`Faculty Research Fellowship Award, The University of Mississippi, 2006 – 2007
`
`AAiPS Research Award, 2004, from American Association of Indian Pharmaceutical
`Scientists (AAiPS).
`
`School of Graduate Studies Distinguished Dissertation Fellowship Award, University of
`Missouri-Kansas City (UMKC), 2004-2005.
`
`
`
`
`
`Dean’s Doctoral Scholar Fellowship, UMKC, 2003-2004
`
`Outstanding Leadership Award in 2003 from School of Pharmacy, UMKC.
`
`Outstanding Leadership Award in 2002 from School of Pharmacy, UMKC.
`
`Chancellor’s Non-Resident (CNR) Award, UMKC, 2000 – 2005.
`
`University gold medal - M.S. program in the Division of Pharmaceutical Technology,
`Jadavpur University, Calcutta, India.
`
`Scholarship from the University Grants Commission (Govt. of India) for the duration of
`the M.S. program (1989-1991).
`
`
`
`ACADEMIC EXPERINCE
`
`COURSES TAUGHT
`
`
` PHAR 331, Basic Pharmaceutics (3 Credit hours), Course Director
` PHAR 433, Industrial Pharmacy (Elective; 2 Credit hours), Course Director
` PHAR 660, Advanced Pharmacokinetics (3 Credit hours), Course Director
`
`Page 2 of 34
`
`

`

` PHAR 541 (2 Credit hours), Course Director
` PRCT 353 (2 Credit hours), Skills Lab I Course co-Instructor (about 30% course load)
` PHAR 649 – Product Development (3 Credit hours), Course Instructor
` PHAR 434, Biopharmaceutics and Pharmacokinetics, 2005-2006 Spring (3 Credit hours)
`Co-Instructor (30% course load)
`
`
`
`RESEARCH GRANTS
`
`
`Current Projects
`
`06/2017 – 05/2021
`
`
`
`
`
`
`1R01AI132579-01
`Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure
`Principal Investigator: B. Tekwani
`Role: co-PI
`Agency: NIH/NIAID
`Total Budget: $ 2,358,656
`
`03/2015 – 02/2019
`
`
`
`
`
`
`1R01EY022120-01A1
`Evaluation and Inhibition of Efflux Pumps Expressed on the Blood Ocular Barrier
`Principal Investigator: S. Majumdar
`Agency: NIH/NEI
`Total Budget: $ 1,489,470
`
`MRI: Acquisition of a Field-Emission Scanning Electron Microscope to support
`multidisciplinary research and education at the University of Mississippi
`Principal Investigator: S. Majumdar
`Agency: NSF
`Total Budget: $ 346,641
`
`P20 GM104932 Center of Research Excellence in Natural
`Product Neuroscience
`Program Director: S. Majumdar
`Agency: NIH/NIGMS
`Total Budget: Approx. $ 2,006,361
`
`
`University of MS Research Foundation
`Pii Center for Pharmaceutical Technology
`Principal Investigator: S. Majumdar
`Project Director: M.A. Repka
`Total Budget: $ 500,000
`
`
`
`
`
`
`
`
`
`
`
`
`09/2016 – 08/2017
`
`09/2012 – 08/2017
`
`
`
`
`Page 3 of 34
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3/27/06 – 4/26/06
`
`10/07/05 – 12/06/05
`
`Completed Projects
`
`Oral Absorption of Hesperidin
`Next Pharmaceuticals, Inc.
`The major goal of this project was to research factors affecting oral absorption of hesperidin.
`Principal Investigator: S. Majumdar
`Total Budget: $ 2,500
`
`
`Berberine Project
`Next Pharmaceuticals, Inc.
`The major goal of this project was to study and improve dissolution of berberine.
`Principal Investigator: S. Majumdar
`Total Budget: $ 12,500
`
` 09/2006-09/2009
`
`P20 RR021929 (Matsumoto/Cutler) NCRR/NIH
`Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)
`Individual Project Proposal: “Characterization, Formulation and Evaluation of THC Pro-drugs
`for Oral Transmucosal Delivery”
`PI of Individual Project: Repka, M.A.
`Co-PI of Individual Project: Majumdar, S
`Total Budget: $ 550,000
`
`
` 09/2007-02/2010
`
`
`
`
`
` R21 EY18426-01 NIH/NEI
`
`Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery.
`
`Principal Investigator: S. Majumdar
` Total Budget: $ 209,829
`
`
`
`
`
`
` 07/2007 – 06/2011
`
`Small Grant Project (Majumdar, S)
`Awarded through NIH/NCRR grant award P20 RR021929 (Cutler) Center of Research
`Excellence in Natural Products Neuroscience (CORE-NPN)
`
`
`Small Grant Project Title: Vitreo-retinal hesperidin concentrations following topical or oral
`administration
`Principal Investigator: S. Majumdar
`
` Total Budget: $ 166,000
`
`
`Center for Thermal Pharmaceutical Processing Phases I & II
`(Health Resources and Services Administration) (Repka, M.A)
` Co-Principal Investigator: S. Majumdar
` Total Budget: $ 895,850
`
` Hot-Melt Extrusion Feasibility Studies for AR-12:
`Preformulation and Accelerated Stability
`Co-Investigator: S. Majumdar
`Other Involvement: REPKA, MICHAEL A - Principal investigator
`Award Type: Business and Industry
`Granting Agency: Other
`Total Budget: $ 40,316
`
` 09/2008 - 08/2011
`
`
`
`
`
`
` 09/2010 - 02/2011
`
`Page 4 of 34
`
`

`

` 2
`
` 06/2008 – 05/2012
`
`
`
` R42 GM067304-02 (ElSohly) NIH/NIGMS
`Project Title: Transmucosal Intra-Oral Drug Delivery System for THC
` Co-Principal Investigator: S. Majumdar
`Total Budget: $ 745,161
`
` 06/2008 – 05/2012
`
`Supplement to 2 R42 GM067304-02 (ElSohly) NIH/NIGMS
`Project Title: Transmucosal Intra-Oral Drug Delivery System for THC
` Co-Principal Investigator: S. Majumdar
` Total Budget: $ 142,200
`
`
` 09/2010 - 08/2013
`
` 03/2011-02/2013
`
` 04/2013 – 09/2013
`
`08/2013 – 07/2015
`
`
`
`
`01/2010 - 12/2014
`
`
`
`
`
`
`Center for Thermal Pharmaceutical Processing (CTP2) Phase III
`Principal Investigator: M.A. Repka
`Co-Principal Investigator: S. Majumdar
`Agency: DHHS
`Total Budget: $ 594,000
`
`
`
`1R41EY020042-01A1 Development of Tetrahydrocannabinol
`prodrugs for topical treatment of Glaucoma”
`Principal Investigator at Research Institution: S. Majumdar
`Agency: NIH/NEI
`Total Budget: $ 136,479
`
`Technology Commercialization Initiative Fund
`Controlled Release Ophthalmic Formulations
`Principal Investigator of Project: S. Majumdar
`Total Budget: $ 15,000
`
`
`
`
`
`1R41AI108113-01
`
`Program Director: ElSohly M.A,
`
`
`
`
`
`
`
`Project PI: ElSohly M.A, Majumdar S
`
` Orally Active Formulations of DHA Dimers for the treatment of Infectious Diseases
`Agency: NIH/NIAID
`Total Budget: $ 205,514
`
`Properties of HME Extruded Films containing Kollidon® VA-64
`and New Polymer, Soluplus®
`
`
`
`
`
`Principal Investigator: M. A. Repka
` Co-PI: S. Majumdar
`Agency: BASF SE
`Type: Research Contract
`Total Budget: $ 146,349
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 5 of 34
`
`

`

`Fundamentals Studies in the Application of Low MW Klucel® and Hot-Melt Extrusion for the
`Oral Delivery of Insoluble Drugs from Tablets, Capsules and Oral Film Dosage Forms
`Principal Investigator: M. A. Repka
`
`
`
`
`01/2010-12/2014
` Co-PI: S. Majumdar
`Agency: Ashland Aqualon
`Type: Research Contract
`Total Budget: $ 187,440
`
`
`
`
`
`PUBLISHED ARTICLES (PEER REVIEWED).
`
`1. Functional Expression of a Sodium Dependent Nucleoside Transporter on Rabbit Cornea:
`Role in Corneal Permeation of Acyclovir and Idoxuridine. Soumyajit Majumdar, Sriram
`Gunda and Ashim K. Mitra. Current Eye Research. 2003 Mar-Apr;26(3-4):175-83.
`2. Drug delivery to retina: challenges and opportunities. Sridhar Duvvuri, Soumyajit Majumdar
`and Ashim K. Mitra. Expert Opinion on Biological Therapy. 2003 Feb;3(1):45-56.
`3. Functional Differences in Nucleoside and Nucleobase Transporters Expressed on the Rabbit
`Corneal Epithelial Cell Line (SIRC) and Isolated Rabbit Cornea. Soumyajit Majumdar,
`Giridhar S. Tirucherai, Dhananjay Pal and Ashim K. Mitra. AAPS PharmSci. 2003;5(2):E15.
`1. Expression of Peptide Transporters on Rabbit Retina: A Strategy to Improve Retinal Delivery
`of Ganciclovir. Soumyajit Majumdar, Sreeraj Macha, Yasser Nashed and Ashim K. Mitra.
`Letters in Drug Design and Discovery. 2004;1(1):73-77.
`5. Membrane Transporter / Receptor Targeted Prodrug Design: Strategies for Human and
`Veterinary Drug Development. Soumyajit Majumdar, Sridhar Duvvuri and Ashim K. Mitra.
`Advanced Drug Delivery Reviews. 2004; 56(10): 1437-1452.
`6. Bioreversion And Oral Bioavailability Of The L-Valine Dipeptide Ester Prodrug Of
`Acyclovir, Val-Valacyclovir, In Sprague-Dawley Rats. Soumyajit Majumdar, Sridhar Duvvuri
`and Ashim K. Mitra. Clinical Research and Regulatory Affairs. 2004; 21(1); 67 – 79.
`7. Circumventing P-gp mediated cellular efflux of quinidine by prodrug derivatization. Ritesh
`Jain, Soumyajit Majumdar, Dhananjay Pal and Ashim K. Mitra. Molecular Pharmaceutics. 2004;
`1(4); 290-299.
`8. Mechanism of Ganciclovir Uptake by Rabbit Retina and Human Retinal Pigmented
`Epithelium Cell Line, ARPE-19. Soumyajit Majumdar, Sreeraj Macha, Dhananjay Pal and
`Ashim K. Mitra. Current Eye Research. 2004 Aug-Sep;29(2-3):127-36.
`9. Role of Metabolism in Ocular Drug Delivery. Sridhar Duvvuri, Soumyajit Majumdar and
`Ashim K. Mitra. Current Drug Metabolism. 2004 Dec;5(6):507-15.
`10. Functional Activity of a Monocarboxylate Transporter, MCT1, in the Human Retinal
`Pigmented Epithelium Cell Line, ARPE-19. Soumyajit Majumdar, Sriram Gunda, Dhananjay
`Pal and Ashim K. Mitra. Molecular Pharmaceutics. 2005 Mar-Apr;2(2):109-17.
`11. Evasion of P-gp Mediated Cellular Efflux and Permeability Enhancement of HIV-Protease
`Inhibitor Saquinavir by Prodrug Modification. Ritesh Jain, Sheetal Agarwal, Soumyajit
`Majumdar, Xiadang Zhu, Dhananjay Pal and Ashim K. Mitra. International Journal of
`Pharmaceutics. 2005 Oct 13;303(1-2):8-19.
`
`Page 6 of 34
`
`

`

`12. Dipeptide Monoester Ganciclovir Prodrugs for Treating HSV-1-induced Corneal Epithelial
`and Stromal Keratitis: In Vitro and In Vivo Evaluations. Soumyajit Majumdar, Yasser E.
`Nashed, Kunal Patel, Ritesh Jain, Motoki Itahashi, Donna M. Neumann, James M. Hill, and
`Ashim K. Mitra. Journal of Ocular Pharmacology and Therapeutics. 21(6):463-74; 2005.
`13. Chemical modification and formulation approaches to elevated drug transport across cell
`membranes. Soumyajit Majumdar and Ashim K. Mitra. Expert Opinion on Drug Delivery.
`2006. 3(4):511-27.
`14. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. Soumyajit
`Majumdar, Viral Kansara, and Ashim K. Mitra. J Ocul Pharmacol Ther. 2006, 22(4):231-41.
`15. Approaches towards enhanced transepithelial drug delivery. Soumyajit Majumdar, and Ashim
`K. Mitra. Discovery Medicine. 2006, 6(36):229-33.
`16. Formulation and evaluation of rapidly disintegrating fenoverine
`tablets: effect of
`superdisintegrant.: Sunil Kumar Battu, Michael A. Repka, Soumyajit Majumdar and
`Madhusudan Rao Y. Drug Development and Industrial Pharmacy. 2007, 33(11):1225-32..
`17. Effect of Chitosan, Benzalkonium Chloride and Ethylenediaminetetraacetic acid on
`Permeation of Acyclovir Across Isolated rabbit cornea. Soumyajit Majumdar, Ketan
`Hippalgaonkar and Michael A. Repka. International Journal of Pharmaceutics. 2008, 348(1-
`2):175-8.
`18. Off-line and on-line measurements of drug-loaded hot-melt extruded films using Raman
`spectroscopy.Tumuluri VS, Kemper MS, Lewis IR, Prodduturi S, Majumdar S, Avery BA,
`Repka MA. International Journal of Pharmaceutics. 2008 Jun 5;357(1-2):77-84. Epub 2008 Feb
`2.
`19. Chemical stability and bioadhesive properties of an ester prodrug of Delta(9)-
`tetrahydrocannabinol in poly(ethylene oxide) matrices: Effect of formulation additives.
`Sridhar Thumma, Soumyajit Majumdar, Mahmoud A. ElSohly, Waseem Gul, Michael A.
`Repka. International Journal of Pharmaceutics. 2008 Oct 1;362(1-2):126-32. Epub 2008 Jul 5.
`20. Preformulation Studies of a Prodrug of Delta(9)-Tetrahydrocannabinol. Sridhar Thumma,
`Soumyajit Majumdar, Mahmoud A. ElSohly, Waseem Gul, Michael A. Repka. AAPS
`PharmSciTech. 2008;9(3):982-90. Epub 2008 Aug 28.
`21. Transcorneal Permeation of l- and d-Aspartate Ester Prodrugs of Acyclovir: Delineation of
`Passive Diffusion Versus Transporter Involvement. Soumyajit Majumdar, Tushar Hingorani,
`Ramesh Srirangam, Rama Sarma Gadepalli, John M. Rimoldi, and Michael A. Repka.
`Pharmaceutical Research. 2009 May;26(5):1261-9. PMCID: PMC2664401
`22. Solubility, Stability, Physicochemical Characteristics and In Vitro Ocular Tissue Permeability
`of Hesperidin: A Natural Bioflavonoid. Soumyajit Majumdar, Tushar Hingorani, Ramesh
`Srirangam. Pharmaceutical Research. 2009 May;26(5):1217-25. PMCID: PMC2664388
`23. Applications of Hot-Melt Extrusion for Drug Delivery. Michael A. Repka., Soumyajit
`Majumdar, Sunil Kumar Battu, Ramesh Srirangam, Sampada Upadhaye. Expert Opinion on
`Drug Delivery. 2008 Dec;5(12):1357-76
`24. Vitreal Kinetics of Quinidine in Rabbits in the Presence of Topically Co-administered P-gp
`Substrates/Modulators: Soumyajit Majumdar, Ketan Hippalgaonkar, Ramesh Srirangam. Drug
`Metabolism and Disposition. 2009 Aug; 37(8):1718-25. PMCID: PMC2712438
`
`Page 7 of 34
`
`

`

`25. Evaluation of Active and Passive Transport Processes in Corneas Extracted from Preserved
`Rabbit Eyes. Soumyajit Majumdar, Tushar Hingorani, Ramesh Srirangam. Journal of
`Pharmaceutical Sciences. 2010 Apr;99(4):1921-30. PMC Journal-In Process.
`26. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. Soumyajit
`Majumdar, Ramesh srirangam. The Journal of Pharmacy and Pharmacology 2010
`Aug;62(8):951-65.
`27. Preparation and Characterization of Inclusion Complexes of a Hemisuccinate Ester Prodrug
`of Δ9-Tetrahydrocannabinol with Modified Beta-Cyclodextrins. Sampada Upadhaye, Swapnil J
`Kulkarni, Soumyajit Majumdar, Mitchell A. Avery, Waseem Gul, Mahmoud A. ElSohly. AAPS
`PharmSciTech. 2010 Jun;11(2):509-17. Epub 2010 Mar 24.
`28. Interaction between Topically and Systemically Co-administered P-glycoprotein
`Substrates/Inhibitors: Effect on Vitreal Kinetics. Ketan Hippalgaonkar, Ramesh Srirangam,
`Bharathi Avula, Ikhlas Khan, Soumyajit Majumdar. In Press. Drug Metabolism and Disposition.
`29. Passive asymmetric transport of hesperetin across isolated rabbit cornea. Ramesh Srirangam,
`Soumyajit Majumdar. International Journal of Pharmaceutics. 2010 Jul 15;394 (1-2):60-7. Epub
`2010 May 9
`30. Physicochemical Characterization of Berberine Chloride: A Perspective in the Development
`of a Solution Dosage Form for Oral Delivery. Sunil Kumar Battu, Soumyajit Majumdar,
`Sindhuri Maddineni, Amar G. Chittiboyina, Mitchell A. Avery, and Michael A. Repka. AAPS
`PharmSciTech. 2010 Sep;11(3):1466-75. Epub 2010 Sep 15.
`31. Enhanced Solubility, Stability and Corneal Permeation of Delta-8-Tetrahydrocannabinol in
`the presence of Cyclodextrins. Soumyajit Majumdar, Ketan Hippalgaonkar, Waseem Gul,
`Mahmoud A. ElSohly and Michael A. Repka. AAPS PharmSciTech. 2011 Jun;12(2):723-31.
`Epub 2011 Jun 3.
`32. Injectable lipid emulsions-advancements, opportunities and challenges. Ketan Hippalgaonkar,
`Soumyajit Majumdar and Viral Kansara. AAPS PharmSciTech. 2010 Dec;11(4):1526-40. Epub
`2010 Oct 26.
`33. Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol
`prodrug: Potential in glaucoma therapy. Tushar Hingorani, Waseem Gul, Mahmoud A
`Elsohly, Repka MA, Majumdar S. J Pharm Sci. 2012 Feb;101(2):616-26.
`34. Intravitreal Kinetics of Hesperidin, Hesperetin and Hesperidin G: Effect of Dose and
`Physicochemical Properties. Ramesh Srirangam, Ketan Hippalgaonkar and Soumyajit
`Majumdar. J Pharm Sci. 2012 Apr;101(4):1631-8. doi: 10.1002/jps.23047. Epub 2012 Jan 6
`35. Stabilization of fenofibrate in low molecular weight hydroxypropylcellulose matrices
`produced by hot-melt extrusion. Weibin Deng, Soumyajit Majumdar, Abhilasha Singh, Sejal
`Shah, Mohammed NN, Seongbong Jo, Elanor Pinto, Divya Tewari, Tom Durig, Michael A
`Repka. Drug Dev Ind Pharm. 2013 Feb;39(2):290-8. doi: 10.3109/03639045.2012.679280. Epub
`2012 Apr 23
`36. Evaluation of the Intravenous and Topical Routes for Ocular Delivery of Hesperidin and
`Hesperetin. Ramesh Srirangam, Ketan Hippalgaonkar, Bharathi Avula, Ikhlas A Khan,
`Soumyajit Majumdar.
`J Ocul Pharmacol Ther.
`2012 Dec;28(6):618-27.
`doi:
`10.1089/jop.2012.0040. Epub 2012 Jul 13.
`
`Page 8 of 34
`
`

`

`37. Klucel™ EF and ELF polymers for immediate-release oral dosage forms prepared by melt
`extrusion technology. Mohammed NN, Majumdar S, Singh A, Deng W, Murthy NS, Pinto E,
`Tewari D, Durig T, Repka MA. AAPS PharmSciTech. 2012 Sep 8. [Epub ahead of print]
`38. Indomethacin-loaded
`solid
`lipid nanoparticles
`for ocular delivery: development,
`characterization, and in vitro evaluation. Hippalgaonkar K, Adelli GR, Hippalgaonkar K,
`Repka MA, Majumdar S. J Ocul Pharmacol Ther. 2013 Mar;29(2):216-28. doi:
`10.1089/jop.2012.0069. Epub 2013 Feb 19.
`39. Phytochemicals in ocular health: Therapeutic potential and delivery challenges. Adelli GR,
`Srirangam R, Majumdar S. World J Pharmacol 2013; 2(1): 1
`40. Development and characterization of taste masked Efavirenz pellets utilizing hot melt
`extrusion. A. Singh, S. Majumdar, W. Deng, N.N. Mohammed, A.G. Chittiboyina, V. Raman,
`S. Shah, M.A. Repka. J. Drug Del. Sci. Tech., 23 (2) 157-163 2013
`41. Ocular Disposition of the Hemiglutarate Ester Prodrug of ∆9-Tetrahydrocannabinol from
`Various Ophthalmic Formulations. Hingorani T, Adelli GR, Punyamurthula N, Gul W, Elsohly
`MA, Repka MA, Majumdar S. Pharm Res. 2013 Jun 5. [Epub ahead of print]
`42. Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing
`design of experiments., S. Maddineni, S. K. Battu, J. Morott, S. Majumdar, M. A. Repka,
`Journal of Pharmacy and Pharmacology, DOI: 10.1111/jphp.12129
`43. Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion. Patil H,
`Kulkarni V, Majumdar S, Repka MA. DOI 10.1016/j.ijpharm.2014.05.024. [Epub ahead of
`print]
`44. Investigation of phase diagrams and physical stability of drug-polymer solid dispersions. Lu J,
`Shah S, Jo S, Majumdar S, Gryczke A, Kolter K, Langley N, Repka MA. Pharm Dev Technol.
`2014 Aug 12:1-13. [Epub ahead of print]
`45. Evaluation of the recrystallization kinetics of hot-melt extruded polymeric solid dispersions
`using an improved Avrami equation. Feng X, Ye X, Park JB, Lu W, Morott J, Beissner B, Lian
`ZJ, Pinto E, Bi V, Porter S, Durig T, Majumdar S, Repka MA. Drug Dev Ind Pharm. 2014 Sep
`16:1-9. [Epub ahead of print]
`46. Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion
`Technology: a Systematic Study Based on a Quality by Design Approach. Patil H, Feng X, Ye
`X, Majumdar S, Repka MA. AAPS J. 2014 Oct 25. [Epub ahead of print]
`47. Influence of Process and Formulation Parameters on Dissolution and Stability
`Characteristics of Kollidon® VA 64 Hot-Melt Extrudates. Maddineni S, Battu SK, Morott J,
`Majumdar S, Murthy SN, Repka MA. AAPS PharmSciTech. 2014 Nov 1. [Epub ahead of print]
`48. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked
`formulations incorporated into orally disintegrating tablets. Morott JT, Pimparade M, Park
`JB, Worley CP, Majumdar S, Lian Z, Pinto E, Bi Y, Durig T, Repka MA. J Pharm Sci. 2015
`Jan;104(1):124-34. doi: 10.1002/jps.24262. Epub 2014 Nov 19.
`49. Stability-enhanced Hot-melt Extruded Amorphous Solid Dispersions via Combinations of
`Soluplus® and HPMCAS-HF. Alshahrani SM, Lu W, Park JB, Morott JT, Alsulays BB,
`Majumdar S, Langley N, Kolter K, Gryczke A, Repka MA. AAPS PharmSciTech. 2015 Jan 8.
`[Epub ahead of print]
`
`Page 9 of 34
`
`

`

`50. Evaluation of topical hesperetin matrix film for back-of-the-eye delivery. Adelli GR,
`Hingorani T, Punyamurthula N, Balguri SP, Majumdar S. Eur J Pharm Biopharm. 2015 Feb 26.
`pii: S0939-6411(15)00087-9. doi: 10.1016/j.ejpb.2015.02.006. [Epub ahead of print]
`51. Effect of Cyclodextrins on Morphology and Barrier Characteristics of Isolated Rabbit
`Corneas.Adelli GR, Balguri SP, Majumdar S. AAPS PharmSciTech. 2015 Mar 14. [Epub
`ahead of print]
`52. Development of taste masked caffeine citrate formulations utilizing hot melt extrusion
`technology and in vitro-in vivo evaluations. Pimparade MB, Morott JT, Park JB, Kulkarni VI,
`Majumdar S, Murthy SN, Lian Z, Pinto E, Bi V, Durig T, Murthy R, H N S, Vanaja K, Kumar
`P C, Repka MA. Int J Pharm. 2015 Jun 20;487(1-2):167-76. doi:
`10.1016/j.ijpharm.2015.04.030. Epub 2015 Apr 15.
`53. Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via
`molecular interaction produced by hot melt extrusion technology. Alshehri SM, Park JB,
`Alsulays BB, Tiwari RV, Almutairy B, Alshetaili AS, Morott J, Shah S, Kulkarni V, Majumdar
`S, Martin ST, Mishra S, Wang L, Repka MA. J Drug Deliv Sci Technol. 2015 Jun 1;27:18-27.
`54. Influence of pressurized carbon dioxide on ketoprofen-incorporated hot-melt extruded low
`molecular weight hydroxypropylcellulose. A Ashour E, Kulkarni V, Almutairy B, Park JB,
`Shah SP, Majumdar S, Lian Z, Pinto E, Bi V, Durig T, Martin ST, Repka MA. Drug Dev Ind
`Pharm. 2015 May 22:1-8. [Epub ahead of print]
`55. Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.
`Punyamurthula NS, Hingorani T, Adelli G, Gul W, ElSohly MA, Repka MA, Majumdar S.
`Drug Dev Ind Pharm. 2015 Dec 7:1-7. [Epub ahead of print]
`56. Influence of Molecular Weight of Carriers and Processing Parameters on the Extrudability,
`Drug Release, and Stability of Fenofibrate Formulations Processed by Hot-Melt Extrusion.
`Alsulays BB, Park JB, Alshehri SM, Morott JT, Alshahrani SM, Tiwari RV, Alshetaili AS,
`Majumdar S, Langley N, Kolter K, Gryczke A, Repka MA. J Drug Deliv Sci Technol. 2015 Oct
`1;29:189-198.
`
`57. Investigation of the combined effect of MgO and PEG on the release profile of mefenamic
`acid prepared via hot-melt extrusion techniques. Alshehri SM, Tiwari RV, Alsulays
`BB, Ashour EA, Alshetaili AS, Almutairy B, Park JB, Morott J, Sandhu B, Majumdar S, Repka
`MA. Pharm Dev Technol. 2016 Jan 29:1-14. [Epub ahead of print]
`
`58. Optimization of hot melt extrusion parameters for sphericity and hardness of polymeric face-
`cut pellets. Alshetaili AS, Almutairy BK, Alshahrani SM, Ashour EA, Tiwari RV, AlshehMA.
`Drug Dev Ind Pharm. 2016 Nov;42(11):1833-41. doi: 10.1080/03639045.2016.1178769
`
`59. Hot melt extrusion as an approach to improve solubility, permeability and oral absorption of
`a psychoactive natural product, piperine. Ashour EA, Majumdar S, Alsheteli A, Alshehri S,
`Alsulays B, Feng X, Gryczke A, Kolter K, Langley N, Repka MA. J Pharm Pharmacol. 2016
`Aug;68(8):989-98. doi: 10.1111/jphp.12579
`
`60. Advances in the use of prodrugs for drug delivery to the eye. Taskar P, Tatke A, Majumdar S.
`Expert Opin Drug Deliv. 2017 Jan;14(1):49-63.
`
`Page 10 of 34
`
`

`

`61. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for
`delivery to the posterior segment ocular tissues. Balguri SP, Adelli GR, Majumdar S. Eur J
`Pharm Biopharm. 2016 Dec;109:224-235. doi: 10.1016/j.ejpb.2016.10.015.
`
`62. Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic
`Formulations. Punyamurthula NS, Adelli GR, Gul W, Repka MA, ElSohly MA, Majumdar S.
`AAPS PharmSciTech. 2017 Aug;18(6):1936-1945. doi: 10.1208/s12249-016-0672-2. Epub
`2016 Nov 30.
`
`63. Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release
`ocular delivery. Adelli GR, Prachetan SB, Bhagav P, Majumdar S. Drug Delivery. 2017
`Nov;24(1):370-379. doi: 10.1080/10717544.2016.1256000.
`
`64. Echinocandins in Ocular Therapeutics. Patil A, Majumdar S. J Ocul Pharmacol Ther 2017
`Jun;33(5):340-352. doi: 10.1089/jop.2016.0186. Epub 2017 Feb 24.
`
`65. Development of a δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved
`ocular bioavailability. Adelli GR, Bhagav P, Taskar P, Hingorani T, Pettaway S, Gul WA,
`ElSohly MA, Repka MA, Majumdar S. Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2167-
`2179. doi: 10.1167/iovs.16-20757.
`
`66. Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery. Balguri SP,
`Adelli GR, Tatke A, Janga KY, Bhagav P, Majumdar S. J Pharm Sci. 2017 Aug 1. pii: S0022-
`3549(17)30552-X. doi: 10.1016/j.xphs.2017.07.017. [Epub ahead of print]PMID:28778424
`
`67. Echinocandins in antifungal pharmacotherapy. Patil A, Majumdar S. J Pharm Pharmacol.
`2017 Jul 26. doi: 10.1111/jphp.12780. [Epub ahead of print] Review.PMID:28744860
`68. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers:
`Effect of molecular weight and density of poly (ethylene) glycol. Balguri SP, Adelli GR, Janga
`KY, Bhagav P, Majumdar S.
`Int J Pharm. 2017 Jun 17;529(1-2):32-43. doi:
`10.1016/j.ijpharm.2017.06.042. [Epub ahead of print]
`69. Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery. Balguri SP,
`Adelli GR, Tatke A, Janga KY, Bhagav P, Majumdar S. J Pharm Sci. 2017 Dec;106(12):3515-
`3523. doi: 10.1016/j.xphs.2017.07.017. Epub 2017 Aug 1.
`70. Current Perspectives on Natamycin in Ocular Fungal Infections. Patil A, Lakhani P,
`Majumdar S. Journal o Drug Delivery Science and Technology. Oct 2017; 41: 206-212
`
`
`
`
`
`BOOK CHAPTER
`
`Transcleral Drug Delivery To The Posterior Segment Of The Eye: Particulate And Colloidal
`Formulations And Biopharmaceutical Considerations. Ramesh Srirangam and Soumyajit
`Majumdar. “Advances in Ocular Drug Delivery”. Edited by Dr. Ashim K. Mitra. Publisher:
`Research Signpost and Transworld Research Network.
`http://www.trnres.com/ebookcontents.php?id=121
`
`
`Page 11 of 34
`
`

`

`Recent patents and regulatory aspects on ophthalmic drug delivery systems. Soumyajit Majumdar,
`Ketan Hippalgaonkar, Tushar Hingorani, Walter G. Chambliss. "Treatise on Ocular Drug Delivery",
`Edited By: Dr. Ashim K. Mitra, ISBN: 978-1-60805-175-5.
`
`Ocular Delivery of Tetrahydrocannabinol. Goutham R. Adelli, Prakash Bhagav, Michael A.
`Repka, Mahmoud A. ElSohly, Soumyajit Majumdar “The Handbook of Cannabis and Related
`Pathologies.”. In Press
`
`
`PATENTS
`“Amino acid ester derivatives of bioactive compounds, and di-, tri, and tetra-peptide ester
`derivatives of bioactive compounds, for therapy”. U.S. Patent 7,214,664 B2.
`
`“Compositions Containing Delta-9-THC-Amino Acid Esters and Process of Preparation.”
`US8809261 B2
`
`“Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux” US 7910553 B2
`
`
`
`INVITED TALKS
`Drug Delivery to the Posterior Segment Ocular Tissues. Seminar series, Harrison School of
`Pharmacy, Auburn University, Auburn, February 21, 2017.
`Topical ocular delivery of antimicrobials – challenges and opportunity. Research in
`Ophthalmology and Vision Sciences 2016 Seminar Series. Department of Ophthalmology,
`University of Mississippi Medical Center, June 2016
`Noninvasive formulation strategies to increase ocular bioavailability. Ophthalmology Grand
`Rounds. Department of Ophthalmology, University of Mississippi Medical Center, Feb 2016
`Can lipid carriers be the future of non-invasive ophthalmic drug delivery. AAPS Annual Meeting.
`Orlando, FL. 2015
`Lipid based drug delivery. Lipid based drug delivery focus group. Lipid Based Drug Delivery
`Focus Group. AAPS Annual Meeting, San Diego, 2014
`Preformulation Testing and Techniques and Early Tablet Formulation Development. Hands-on
`Course in Tablet Technology, University of Mississippi, Mississippi, June 2, 2014.
`Preformulation Testing and Techniques and Early Tablet Formulation Development. Hands-on
`Course in Tablet Technology, University of Mississippi, Mississippi, March 3, 2014.
`Preformulation Testing and Techniques and Early Tablet Formulation Development. Hands-on
`Course in Tablet Technology, University of Mississippi, Mississippi, September 23, 2013.
`Modulation of Efflux Activity of P-Glycoprotein Expressed on the Retinal Pigmented Epithelium
`- Impact on Ocular Drug Delivery. Asia-ARVO 2009, Hyderabad, India. January 17, 2009
`Developing Liquid Modified Release Dosage Forms: Preformulation and Formulation
`Considerations. AAPS Annual Meeting, Washington DC, 2011
`
`
`Page 12 of 34
`
`

`

`
`PRESENTATIONS:
`
`AAPS (Association of Pharmaceutical Scientists)
`
`
`1. Enhanced Delivery of Ciprofloxacin into the Ocular Tissues from Topical Nanostructured
`Lipid Carriers: Effect of Surface Functionalization S. P. Balguri , G. Adelli , S. Majumdar.
`University of Mississippi, 2 Insys Therapeutics, Inc. AAPS Annual Meeting 2016, Denver,
`Colorado.
`2. Ocular Delivery of Resveratrol for the Treatment of Diabetic Retinopathy: Formulation
`Preparation and Characterization. Balguri, Sai Prachetan, Majumdar, Soumyajit. AAPS
`Annual Meeting 2016, Denver, Colorado.
`3. Double Extrusion as a Novel Approach for Product Development. Pimparade, Manjeet,
`Park, J., Vo, Anh, Feng, Xin, Majumdar, S., Lian, Zhuoyang, Bi, Vivian, Durig, Thomas,
`Repka, Michael. AAPS Annual Meeting 2016, Denver, Colorado.
`4. Enhancement in the Transcorneal Permeation of Fluorescein via Bilosomes: Formulation
`and In Vitro Evaluation. Janga, Karthik, Tatke, Akshaya, Ashour, Eman, Majumdar,
`Soumyajit. AAPS Annual Meeting 2016, Denver, Colorado.
`5. Distribution of Fluorescein in Aqueous Humor and Vitreous Humor from the Systemic
`Circulation following Intravenous Administration in Sprague Dawley Rats. Janga, Karthik,
`Tatke, Akshaya, Ashour, Eman, Majumdar, Soumyajit. AAPS Annual Meeting 2016,
`Denver, Colorado.
`6. Optimization and Characterization of Curcumin Loaded Nanostructured Lipid Carriers for
`Ocular Drug Delivery. Lakhani, Prit, Ashour, Eman, Majumdar, Soumyajit. AAPS Annual
`Meeting 2016, Denver, Colorado.
`7. Ocular Distribution of Loperamide HCl in Wild Type and MDR 1A Knock Out Sprague
`Dawley Rats: Impact of P-Glycoprotein. Tatke, Akshaya, Janga, Karthik, Ashour, Eman,
`Jablonski, Monica, Avula, Bharathi, Majumdar, Soumyajit. AAPS Annual Meeting 2016,
`Denver, Colorado.
`8. Effect of a Single vs Multiple Day Regimen of Δ9-THC-Valine-Hemisuccinate on the
`Intraocular Pressure Lowering Activity in Normotensive Rabbits. Taskar, Pranjal, Ashour,
`Eman, Lakhani, Prit, Gul, Waseem, ElSohly, Mahmoud, Majumdar, Soumyajit. AAPS
`Annual Meeting 2016, Denver, Colorado.
`9. Formulation development and characterization of Amphotericin B
`lipid
`loaded
`nanoparticles. Lakhani, Prit, As